12Suppliers
13Customers
3Debt Items
0Related Chains

Source-Backed Evidence Depth

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships
6Distinct source URLs
21High confidence
0.816Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Shuttle Pharmaceuticals Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
1542770-BC-LTD 1542770-BC-LTD 92% Pursuant to the terms and conditions of the Second Amendment, on the Effective Date, the Acquiror (i) issued 270 shares of Series B-1 Convertible Preferred Stock to Seller (such shares, the "Seller B…
E-F-HUTTON-CO E-F-HUTTON-CO 92% In connection with the Merger, the Acquiror issued to E.F. Hutton & Co. (i) 750 shares of Series B-1 Preferred Stock convertible, subject to Requisite Approval, into 3,024,749 shares of Acquiror Comm…
IR-AGENCY IR-AGENCY 92% As consideration for the performance of the Services, the Company paid IR Agency $1.5 million.
IR-AGENCY-LLC IR-AGENCY-LLC 92% As consideration for the performance of the services, the Company paid $ 1.25 million to IR Agency.
ZHITIAN-ANDY-ZHANG ZHITIAN-ANDY-ZHANG 92% Pursuant to the terms and conditions of the Second Amendment, on the Effective Date, the Acquiror (i) issued 270 shares of Series B-1 Convertible Preferred Stock to Seller (such shares, the "Seller B…
1542770-B-C-LTD 1542770-B-C-LTD 90% In exchange for the acquired assets, the Company agreed to pay the Selling Parties (i) a cash payment of $ 3,000,000 at Closing, (ii) a first installment of $ 3,000,000 payable six months after Closi…
1563868-B-C-LTD 1563868-B-C-LTD 90% Pursuant to the terms and conditions of the Second Amendment, on the Effective Date, the Acquiror (i) issued 270 shares of Series B-1 Convertible Preferred Stock to Seller (such shares, the "Seller B…
ALTO-OPPORTUNITY-MASTER-FUND-SPC-SEGREGATED-MAST ALTO-OPPORTUNITY-MASTER-FUND-SPC-SEGREGATED-MAST 90% Amendment No. 1 to the Amendment Agreement, dated June 4, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC – Segregated…
BROWN-UNIVERSITY-LIFESPAN-RHODE-ISLAND-HOSPITAL BROWN-UNIVERSITY-LIFESPAN-RHODE-ISLAND-HOSPITAL 90% Subcontract to Brown University/LifeSpan Rhode Island Hospital.
GEORGETOWN-UNIVERSITY GEORGETOWN-UNIVERSITY 90% 10.52 License Agreement, dated October 24, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc. and Georgetown University
SRO-LLC SRO-LLC 90% 10.54 Securities Purchase Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Diagnostics, Inc. and SRO LLC
THERADEX-SYSTEMS-INC THERADEX-SYSTEMS-INC 80% the Company received a letter from Theradex Systems, Inc., providing written notice of termination of the master agreement

Shuttle Pharmaceuticals Holdings, Inc. Customers

TickerNameConfidenceEvidence
1563868-B-C-LTD 1563868-B-C-LTD 92% Shuttle Pharmaceuticals Holdings, Inc. entered into a First Amendment to Asset Purchase Agreement with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary
SHUTTLE-MERGER-SUB-INC SHUTTLE-MERGER-SUB-INC 92% On May 6, 2026 (the " Closing Date "), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (" Shuttle " or " Acquiror "), completed its previously announced merger pursuant to an Agreement…
UNITED-DOGECOIN-INC UNITED-DOGECOIN-INC 92% On May 6, 2026 (the " Closing Date "), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (" Shuttle " or " Acquiror "), completed its previously announced merger pursuant to an Agreement…
CERTAIN-ACCREDITED-INVESTORS CERTAIN-ACCREDITED-INVESTORS 90% As previously announced, on April 30, 2026, the Acquiror entered into a Securities Purchase Agreement (the " Securities Purchase Agreement ") with certain accredited investors party thereto (each, a …
ALTERNATIVE-INVESTMENT-CAPITAL-INC ALTERNATIVE-INVESTMENT-CAPITAL-INC 62% arising from breaches of representations, warranties, and covenants and specified pre-/post-closing liabilities, subject to customary limitations such as survival periods, thresholds, and caps. The t…
B-C-LTD B-C-LTD 62% ent or in information provided pursuant to certain disclosure schedules to the Merger Agreement. In the Merger Agreement, the Company made certain customary representations to Acquiror including amon…
BC-LTD BC-LTD 62% ent or in information provided pursuant to certain disclosure schedules to the Merger Agreement. In the Merger Agreement, the Company made certain customary representations to Acquiror including amon…
COMPANY-SHUTTLE-DIAGNOSTICS-INC COMPANY-SHUTTLE-DIAGNOSTICS-INC 62% 3,992,675 Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of $ 322,501 5,409,673 — Proceeds from issuance of common stock and pre-funded warrants, net of …
IR-AGENCY-LLC IR-AGENCY-LLC 62% shares of common stock, with an exercise price of $ 3.38 per share, as adjusted, valued at inception at $ 1.1 million and as of December 31, 2025, at less than $ 0.1 million. The Company determined t…
SHUTTLE-PHARMA-ACQUISITION-CORP-INC SHUTTLE-PHARMA-ACQUISITION-CORP-INC 62% S FROM INVESTING ACTIVITY: Payments made for capitalized software ( 36,000 ) — Net cash used in investing activity ( 36,000 ) — CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of note payable-related…
SHUTTLE-PHARMACEUTICALS-INC SHUTTLE-PHARMACEUTICALS-INC 62% S FROM INVESTING ACTIVITY: Payments made for capitalized software ( 36,000 ) — Net cash used in investing activity ( 36,000 ) — CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of note payable-related…
SHUTTLE-PHARMACEUTICALS-LLC SHUTTLE-PHARMACEUTICALS-LLC 62% S FROM INVESTING ACTIVITY: Payments made for capitalized software ( 36,000 ) — Net cash used in investing activity ( 36,000 ) — CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of note payable-related…
WESTPARK-CAPITAL-INC WESTPARK-CAPITAL-INC 62% arising from breaches of representations, warranties, and covenants and specified pre-/post-closing liabilities, subject to customary limitations such as survival periods, thresholds, and caps. The t…

Shuttle Pharmaceuticals Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SHPH-DEBT-12521 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
SHPH-DEBT Debt stack $91,021 90% Market cache reports total debt of $91,021.
SHPH-DEBT-12520 Warrants outstanding: 329461 90% xbrl warrant detail from xbrl 2026-02-28.

Shuttle Pharmaceuticals Holdings, Inc. Acquisitions

Acquired EntityNameConfidenceEvidence
SHPH-ACQ-0001493152-26-020830 The Acquiror entered into a Securities Purchase Agreement to issue $11,000,000 of Series B-2 con... 85% The Acquiror entered into a Securities Purchase Agreement to issue $11,000,000 of Series B-2 convertible preferred stock and warrants.

Shuttle Pharmaceuticals Holdings, Inc. Ownership

HolderNameConfidenceEvidence
SHPH-OWNER-BARCLAYS-PLC BARCLAYS PLC 90% 13F overlay lists BARCLAYS PLC as top holder; 1 tracked holders.

Shuttle Pharmaceuticals Holdings, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.
🔐
SHPH
Unlock SHPH Supply Chain Data
Verified relationships include:
1542770-BC-LTD1542770-BC-LTDSupplier92%
E-F-HUTTON-COE-F-HUTTON-COSupplier92%
1563868-B-C-LTD1563868-B-C-LTDCustomer92%
SHUTTLE-MERGER-SUB-INCSHUTTLE-MERGER-SUB-INCCustomer92%
+26 more relationships locked
Subscribe — View plans →